Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Roche Holding AG Basel American Depositary Shares
(OP:
RHHBY
)
30.41
+0.36 (+1.20%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
18,593,670
Open
30.20
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
30.05
Today's Range
30.20 - 30.50
52wk Range
29.95 - 40.48
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer
April 18, 2024
From
Genentech
Via
Business Wire
Genentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS
April 17, 2024
From
Genentech
Via
Business Wire
Performance
YTD
-16.34%
-16.34%
1 Month
-6.77%
-6.77%
3 Month
-13.95%
-13.95%
6 Month
-8.84%
-8.84%
1 Year
-21.93%
-21.93%
More News
Read More
Roche's Lymphoma Drug With Chemo Extends Survival In Pretreated Patients
April 15, 2024
Via
Benzinga
Genentech’s Columvi Meets Primary Endpoint of Overall Survival in People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Study
April 15, 2024
From
Genentech
Via
Business Wire
Looking for an Easy Way to Earn Passive Income? This Vanguard ETF Pays a Dividend Yield of Nearly 4.9%.
April 14, 2024
Via
The Motley Fool
Topics
ETFs
Why Roche Holdings Stock Popped Today
April 11, 2024
Via
The Motley Fool
Can Recursion Pharmaceuticals Stock Double in 5 Years? Here's What It Would Take.
April 10, 2024
Via
The Motley Fool
Analysts Express Confidence in Alnylam's Hypertension Drug Despite Mixed Trial Data
April 08, 2024
Via
Benzinga
Why Sarepta's First-Quarter Report Is Already Dead In The Water: Analyst
April 08, 2024
Via
Investor's Business Daily
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
March 28, 2024
Via
Investor's Business Daily
Exposures
Product Safety
Hot Stocks: The 3 Best Opportunities for Investing in Weight Loss Drugs
March 22, 2024
Via
InvestorPlace
Why Is European Pharma Giant Argenx Valued At Over $20B Trading Higher On Thursday?
March 21, 2024
Via
Benzinga
Swiss Healthcare Manufacturing Firm Lonza Bolsters Biologics Manufacturing Capacity With Roche's US Facility Acquisition For $1.2B
March 20, 2024
Via
Benzinga
FDA Approves BeiGene's First Drug Candidate Produced Through Its Immuno-Oncology Program For Esophageal Cancer
March 15, 2024
Via
Benzinga
Exposures
Product Safety
Top Wall Street Analysts Flag US Market Concentration Anxiety, Advise Investors To Adopt 'Barbell Approach'
March 11, 2024
Via
Benzinga
Pharma Stock Roundup: Novo Nordisk's New Obesity Pill Data, Roche, AstraZeneca's Pipeline Updates
March 09, 2024
Via
Talk Markets
Exposures
Product Safety
FDA Conditionally Approves Expanded Use Of BeiGene's Combination Drug For Certain Type Of Blood Cancer
March 08, 2024
Via
Benzinga
Exposures
Product Safety
Roche/Alnylam Blood Pressure Drug Aces In Mid-Stage Trial, Analyst Says Zilebesiran As Promising Opportunity In Addressing Global Hypertension Challenges
March 05, 2024
Via
Benzinga
11 'Granolas' Stocks Outperform Magnificent 7 With Lower Volatility, Higher Yields
February 28, 2024
Via
Benzinga
Celldex Stock Hits 11-Month High, Up 19%, On A Promising New Hives Treatment
February 26, 2024
Via
Investor's Business Daily
This Drug By Roche And Novartis Reduces Allergic Reactions Across Multiple Foods For People With Food Allergies
February 26, 2024
Via
Benzinga
New England Journal of Medicine Publishes Phase III Data Showing Xolair Significantly Reduced Allergic Reactions Across Multiple Foods in People With Food Allergies
February 25, 2024
From
Genentech
Via
Business Wire
Move Over Magnificent 7, Say Hello to the GRANOLAS
February 22, 2024
Via
InvestorPlace
FDA Fast-Tracks Review Of Sarepta's Groundbreaking Muscular Dystrophy Treatment With $1B Market In Sight
February 16, 2024
Via
Benzinga
Exposures
Product Safety
FDA Approves Xolair as First and Only Medicine for Children and Adults With One or More Food Allergies
February 16, 2024
From
Genentech
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.